A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

Prof Lucy Yardley, theme lead for behavioural science

Description
NIHR Southampton Biomedical Research Centre Auto Generated Title With extensive experience developing digital interventions, Prof Lucy Yardley is leading our research
Url
/ClinicalResearchinSouthampton/Our-people/Behavioural-science-people/Prof-Lucy-Yardley-theme-lead-for-behavioural-science.aspx

Prof Mark Hanson, research lead for childhood development and health

Description
NIHR Southampton Biomedical Research Centre Auto Generated Title Research lead for LifeLab and the centre's research into childhood obesity, growth, development and health, Professor Mark Hanson has a personal focus on the early origins of non-communicable diseases including obesity, heart disease and diabetes. Nutritional influences on early development Mark ’ s current research centres on how maternal nutrition during foetal development affects the way that inherited genes operate. This influences how as individuals we respond to our environment and different lifestyles, and has implications for the risk of disease later in our lives. These epigenetic mechanisms (factors affecting how and when genes are expressed) are distinct from the genes which we have inherited themselves, often with significant influence over genetic contribution to disease risk and health. This work is allowing us to determine how epigenetic mechanisms may indicate risk of later disease, and how they could be used to help prevent individuals developing such disease through targeted interventions. International policy and advocacy Mark is the current president of the International Society for the Developmental Origins of Health and Disease; he is involved in consultancy and advocacy work with many organisations across the developed and developing worlds, including the World Health Organisation. Promoting health literacy Mark has a particular interest in the opportunities for education to promote health literacy in adolescents, as a way of reducing their disease risk in later life - and to give their future children, the next generation, a healthy start to life. Trained as a physiologist and a teacher and having devoted the last forty years of his life to education and academic work to promote health in the population, Mark was one of the founders of the LifeLab initiative in Southampton.
Url
/ClinicalResearchinSouthampton/Our-people/Nutrition-research-people/Prof-Mark-Hanson-research-lead-for-childhood-development-and-health.aspx

Volunteers needed to optimise steroid doses in patients with asthma

Description
Auto Generated Title We are looking for volunteers aged 18 to 80, with a diagnosis of asthma to take part in a new research aiming to improve use of steroids in patients with severe asthma. RASP study Many people with severe asthma are routinely prescribed medicine containing corticosteroids (steroids) to help control their symptoms. However, high doses of steroids can potentially lead to side-effects, making lower doses preferable for maintaining individuals ’ quality of life – a difficult balance to achieve. In Refractory Asthma Stratification Programme (RASP) study, we aim to explore if doses of steroids (both inhaled and oral) can be optimised in patients with severe asthma, without causing a worsening of the asthma symptoms. We hope to identify those patients who benefit from higher doses of steroids and those who do not. This will be done by looking at markers of asthma in their blood and exhaled breath, and by using these to optimise the steroid dose. In addition, identifying which symptoms and aspects of asthma do not respond well to steroid treatment may allow drug companies to develop new treatments for asthma. This study is part of a larger programme of studies, called RASP-UK. It is being conducted by a group of clinical and academic experts from UK Universities and NHS Severe Asthma Centres, together with pharmaceutical companies with an interest in asthma. Taking part We are recruiting people in the UK to programmes like RASP-UK who: Are aged 18 to 80, with a diagnosis of asthma Take a number of inhaled medications plus occasional or regular oral corticosteroids Have a smoking history of less than 15 pack years This type of study has two stages: Screening (up to 2 weeks) Single-blind study period (up to 48 weeks). Participants in such trials have an equal chance of being randomly selected to be put into the blood and breath marker group or the usual group. At no point will your safety or care be compromised. Travel expenses for clinic visits that are additional to usual appointments will be provided. Contact us If you would like to find more information, please contact Yvette Thirlwall or Gabriela Grumazescu , or contact us on 02381208427 or 0238120449. Please note that enquiring about participation does not commit you to taking part in our trials in any way.
Url
/ClinicalResearchinSouthampton/Public-and-patients/Featured-research-studies/Featuredresearchoptimise-steroid-doses-in-patients-with-asthma.aspx

Featured research: fighting lung disease

Description
Auto Generated Title Southampton researchers are looking for healthy people between 60 and 85 years of age to take part in a study aiming to improve care for those with the respiratory condition chronic obstructive pulmonary disease (COPD). It aims to better understand the role of lung infections in making the condition ’ s effects worse, to inform development of new treatments. Fighting lung disease COPD is a chronic lung condition which affects around 3 million people in the UK , causing breathing difficulties, coughing, wheezing, made worse – often life threatening - by infections and illness. The Microbiology & Immunology of the Chronically-Inflamed Airway II (MICA II) study aims to enhance our understanding of the role of small airways disease in COPD exacerbations by comparing people with COPD and those who have no diagnosed lung conditions. It forms part of our wider programme of COPD research, all aimed at improving care and quality of life for those with the condition. Taking part The COPD research team are keen to hear from healthy people interested in taking part in studies like MICA II, to contribute to better COPD care. Typically these studies involve a number of respiratory tests and assessments at University Hospital Southampton; we want to hear from you if you can spare time to see us for 4 – 5 visits and are: Aged 60 to 85 years and in good health Either an ex-smoker or have never smoked Have no diagnosed respiratory conditions All travel expenses you incur will be remunerated together with payment for your time. To find out more, please contact Sarah Bawden sarah.bawden@uhs.nhs.uk or Pedro Rodrigues pedro.rodrigues@uhs.nhs.uk , or contact us on on 023 8120 4479.
Url
/ClinicalResearchinSouthampton/Public-and-patients/Featured-research-studies/Featured-research-fighting-lung-disease.aspx

What does vulnerable adult mean?

Description
Auto Generated Title From the perspective of UHS, a vulnerable adult is a patient who is or may be for any reason unable to take care of him or herself, or unable to protect him or herself against significant harm or exploitation. It is important to note that no mention of capacity or competence appears in our definition. Whilst it is clear that any patient who lacks capacity will by definition be vulnerable, many patients with capacity may still be unable to take care of themselves, or unable to protect themselves from significant harm or exploitation; often due to the infirmity that lead them to become patients in the first place. Please also note that a vulnerable adult with capacity is perfectly entitled to refuse to let us pass on their personal details to other agencies. Irrespective of the clinical viewpoint of the situation, we must first make it clear to the patient that they may be disadvantaged by this non-disclosure; but providing they have capacity to make this decision, we must abide by their wishes. (It is accepted that under certain circumstances disclosure is mandatory, such as declarations to the DVLA, but you will understand that this note applies to broader principles of clinical practice.) However, an adult in this situation cannot control the disclosure of information to other agencies relating to children for whom they have responsibility. If it is in the child’s interest for other agencies to be aware of family circumstances, for instance relating to domestic violence, the parent's refusal must not prevent disclosure.
Url
/HealthProfessionals/Clinical-law-updates/Whatismeantbyavulnerableadult.aspx

Audit and Risk Committee ToR March 2026

Description
Audit and Risk Committee Terms of Reference Version: 8 Date Issued: Review Date: Document Type: 10 March 2026 January 2027 Committee Terms of Reference Contents Paragraph 1 2 3 4 5 6 7 8 9 10 Role and Purpose Constitution Membership Attendance and Quorum Frequency of Meetings Conduct and Administration of Meetings Duties and Responsibilities Accountability and Reporting Review of Terms of Reference and Performance and Effectiveness References Appendices Appendix A Committee and Reporting Structure Page 2 2 2 3 3 3 4 6 6 6 Page 7 Document Status This is a controlled document. Whilst this document may be printed, the electronic version posted on the intranet is the controlled copy. Any printed copies of this document are not controlled. As a controlled document, this document should not be saved onto local or network drives but should always be accessed from the intranet. Page 1 of 8 1. Role and Purpose 1.1 The Audit and Risk Committee (the Committee) is responsible for overseeing, monitoring and reviewing corporate reporting, the adequacy and effectiveness of the governance, risk management and internal control framework and systems and areas of legal and regulatory compliance at University Hospital Southampton NHS Foundation Trust (UHS or the Trust) and the external and internal audit functions. 1.2 The Committee provides the board of directors of the Trust (the Board) with a means of independent and objective review of financial and corporate governance, assurance processes and risk management across the whole of the Trust’s activities both generally and in support of the annual governance statement. 1.3 The duties and responsibilities of the Committee are more fully described in paragraph 7 below. 2. Constitution 2.1 The Committee has been established by the Board. The Committee has no executive powers other than those set out in these terms of reference. It is supported in its work by other committees established by the Board as shown in Appendix A. 2.2 The Committee is authorised by the Board to investigate any activity within its terms of reference. It is authorised to seek any information it requires from any member of staff and all members of staff are directed to cooperate with any request made by the Committee. 2.3 In carrying out its role the Committee will primarily utilise the work of internal audit, external audit and other assurance functions. It is also authorised to seek reports and assurance from executive directors and managers and will maintain effective relationships with the chairs of other Board committees to understand their processes of assurance and links with the work of the Committee. 2.4 The Committee is authorised to obtain external legal or other independent professional advice if it considers this necessary, taking into consideration any issues of confidentiality and the Trust’s standing financial instructions. 3. Membership 3.1 The members of the Committee will be appointed by the Board and will be independent non-executive directors of the Trust (other than the chair of the Board). The Committee will consist of not less than three members, at least one of whom will have recent and relevant financial experience, ideally with a qualification from one of the professional accountancy bodies. 3.2 The Board will appoint the chair of the Committee from among its members (the Committee Chair).The Committee Chair may be the deputy chair of the Board. However, in the event that the deputy chair must act as chair of the Board for an extended period of time, the deputy chair will resign as Committee Chair. In the absence of the Committee Chair and/or an appointed deputy, the remaining members present will elect one of themselves to chair the meeting. 3.3 Only members of the Committee have the right to attend and vote at Committee meetings. However, the following will be invited to attend meetings of the Committee on a regular basis: 3.3.1 representative(s) from the external auditor; 3.3.2 representative(s) from the internal auditor; Page 2 of 8 3.3.3 representative(s) from the local counter fraud service; 3.3.4 Chief Financial Officer; 3.3.5 Chief Nursing Officer; and 3.3.6 Associate Director of Corporate Affairs/Company Secretary. 3.4 The Chief Executive Officer will be invited to attend meetings of the Committee, at least annually, to discuss with the Committee the process for assurance that supports the annual governance statement. 3.5 Other individuals may be invited to attend for all or part of any meeting, as and when appropriate and necessary, particularly when the Committee is considering areas of risk or operation that are the responsibility of a particular executive director or manager. 3.6 Governors may be invited to attend meetings of the Committee. 4. Attendance and Quorum 4.1 Members should aim to attend every meeting and should attend a minimum of 75% of meetings held in each financial year. Where a member is unable to attend a meeting they should notify the Committee Chair or Company Secretary in advance. 4.2 The quorum for a meeting will be two members. A duly convened meeting of the Committee at which a quorum is present will be competent to exercise all or any of the authorities, powers and discretions vested in or exercisable by the Committee. 4.3 When an executive director or manager is unable to attend a meeting they should appoint a deputy to attend on their behalf. 5. Frequency of Meetings 5.1 The Committee will meet at least four times each year and otherwise as required. 5.2 At least once each financial year the Committee will meet with representatives of the external and internal auditors without management being present to discuss their remit and any issues arising from their audits. 5.3 Outside of the formal meeting programme, the Committee Chair will maintain a dialogue with key individuals involved in the Trust’s governance, including the chair of the Board, the Chief Executive Officer, the Chief Financial Officer, the Chief Nursing Officer, the external audit lead partner and the head of internal audit. 6. Conduct and Administration of Meetings 6.1 Meetings of the Committee will be convened by the secretary of the Committee at the request of the Committee Chair or any of its members, or at the request of external or internal auditors if they consider it necessary. 6.2 The agenda of items to be discussed at the meeting will be agreed by the Committee Chair with support from the Chief Financial Officer and the Company Secretary. The agenda and supporting papers will be distributed to each member of the Committee and the regular attendees no later than five working days before the date of the meeting. Distribution of any papers after this deadline will require the agreement of the Committee Chair. 6.3 The secretary of the Committee will minute the proceedings of all meetings of the Committee, including recording the names of those present and in attendance and any declarations of interest. 6.4 Draft minutes of Committee meetings and a separate record of the actions to be taken forward will be circulated promptly to all members of the Committee. Once approved by Page 3 of 8 the Committee, minutes will be circulated to all other members of the Board unless it would be inappropriate to do so in the opinion of the Committee Chair. 7. Duties and Responsibilities The Committee will carry out the duties below for the Trust. 7.1 Integrated Governance, Risk Management and Internal Control 7.1.1 The Committee will review the establishment and maintenance of an effective system of integrated governance, risk management and internal control across the whole of the Trust’s activities (clinical and non-clinical), that supports the achievement of the Trust’s objectives. In particular, the Committee will review the adequacy and effectiveness of: 7.1.1.1 all risk and control related disclosure statements (in particular the annual governance statement), together with the head of internal audit opinion, external audit opinion or other appropriate independent assurances, prior to submission to the Board; 7.1.1.2 the underlying assurance processes that indicate the degree of achievement of the Trust’s objectives, the effectiveness of the management of principal risks and the appropriateness of annual disclosure statements; and 7.1.1.3 the policies and arrangements for ensuring compliance with relevant regulatory, legal and code of conduct requirements and any related reviews, reporting and selfcertifications, including the NHS Constitution, the Trust’s NHS provider licence, registration with the Care Quality Commission and the Trust’s constitution, standing orders and standing financial instructions and management of conflicts of interest. 7.2 Internal Audit 7.2.1 The Committee will ensure that there is an effective internal audit function that meets the Public Sector Internal Audit Standards and provides appropriate independent assurance to the Committee, Accounting Officer and Board. This will be achieved by: 7.2.1.1 considering the provision of the internal audit service and the costs involved; 7.2.1.2 reviewing and approving the annual internal audit plan and more detailed programme of work, ensuring that this is consistent with the audit needs of the Trust as identified in any risk assessment; 7.2.1.3 considering the major findings of internal audit work (and the appropriateness and implementation of management responses) and ensuring coordination between the internal and external auditors to optimise audit resources; 7.2.1.4 ensuring the internal audit function is adequately resourced and has appropriate standing within the Trust; and 7.2.1.5 monitoring the effectiveness of internal audit and carrying out an annual review. 7.3 External Audit 7.3.1 The Committee will review and monitor the external auditors’ integrity, independence and objectivity and the effectiveness of the external audit process. In particular, the Committee will review the work and findings of the external auditors and consider the implications and management’s response to their work. This will be achieved by: 7.3.1.1 considering the appointment and performance of the external auditors, including providing information and recommendations to the council of governors in connection with the appointment, reappointment and removal of the external auditors in line with criteria agreed by the council of governors and the Committee; Page 4 of 8 7.3.1.2 discussing and agreeing with the external auditors, before the external audit commences, the nature and scope of the audit as set out in the annual external audit plan; 7.3.1.3 discussing with the external auditors their evaluation of audit risks and assessment of the Trust and the impact on the audit fee; 7.3.1.4 reviewing all external audit reports, including reports addressed to the Board and the council of governors, and any work undertaken outside the annual external audit plan, together with any significant findings and the appropriateness and implementation of management responses; and 7.3.1.5 ensuring that there is in place a clear policy for the engagement of external auditors to supply non-audit services taking into account relevant ethical guidance. 7.4 Financial Reporting 7.4.1 The Committee will monitor the integrity of the financial statements of the Trust and any formal announcements relating to the Trust’s financial performance. 7.4.2 The Committee will ensure that the systems for financial reporting to the Board, including those of budgetary control, are subject to review as to the completeness and accuracy of the information provided to the Board. 7.4.3 The Committee will review the annual report and financial statements before these are presented to the Board in order to determine their completeness, objectivity, integrity and accuracy and the letter of representation addressed to the external auditors from the Board. This review will cover but is not limited to: 7.4.3.1 the annual governance statement and other disclosures relevant to the work of the Committee; 7.4.3.2 areas where judgment has been exercised; 7.4.3.3 appropriateness and adherence to accounting policies and practices; 7.4.3.4 explanation of estimates or provisions having material effect and significant variances; 7.4.3.5 the schedule of losses and special payments, which will also be reported on separately during the financial year; 7.4.3.6 any significant adjustments resulting from the audit and unadjusted audit differences; and 7.4.3.7 any reservations and disagreements between the external auditors and management which have not been satisfactorily resolved. 7.4.4 The Committee will provide advice, where requested by the Board, on whether the annual report and accounts, taken as a whole, are fair, balanced and understandable, and provide the information necessary for stakeholders to assess the Trust’s position and performance, business model and strategy. 7.5 Counter Fraud 7.5.1 The Committee will review the effectiveness of arrangements in place for counter fraud, anti-bribery and corruption to ensure that these meet the NHS Counter Fraud Authority’s standards and the outcomes of work in these areas, including reports and updates on the investigation of cases from the local counter fraud service. 7.6 Raising Concerns/Freedom to Speak Up 7.6.1 The Committee will review the effectiveness of the arrangements in place for allowing staff and contractors to raise (in confidence) concerns and possible improprieties in Page 5 of 8 financial, clinical or safety matters and ensure that any such concerns are investigated proportionately and independently with appropriate follow-up action and safeguards in place for those who raise concerns. 7.6.2 The Committee will ensure that the Trust’s policy reflects the minimum standards for raising concerns set out by NHS Improvement and that the arrangements in place are regularly audited. 8. Accountability and Reporting 8.1 The Committee Chair will report to the Board following each meeting, drawing the Board’s attention to any matters of significance or where actions or improvements are needed. 8.2 The Committee will report to the Board at least annually on its work in support of the annual governance statement, specifically commenting on: 8.2.1 the fitness for purpose of the board assurance framework; 8.2.2 the completeness and maturity of risk management in the Trust; 8.2.3 the integration of governance arrangements; 8.2.4 the appropriateness of the self-assessment of the effectiveness of the system of internal control and the disclosure of any significant internal control issues in the annual governance statement. 8.3 The Trust’s annual report will include a section describing the work of the Committee in discharging its responsibilities including: 8.3.1 the significant issues that the Committee considered in relation to financial statements, operations and compliance, and how these issues were addressed; 8.3.2 an explanation of how the Committee has assessed the effectiveness of the external audit process and the approach taken to the appointment or reappointment of the external auditor, the value of external audit services and information on the length of tenure of the current audit firm and when a tender was last conducted; and 8.3.3 if the external auditor provides non-audit services, the value of the non-audit services provided and an explanation of how auditor objectivity and independence are safeguarded. 9. Review of Terms of Reference and Performance and Effectiveness 9.1 At least once a year the Committee will review its collective performance and its terms of reference. Any proposed changes to the terms of reference will be recommended to the Board for approval in consultation with the council of governors. 10. References 10.1National Health Service Act 2006 10.2Code of Governance for NHS Provider Trusts 10.3NHS Foundation Trust Annual Reporting Manual 10.4National Audit Office Code of Audit Practice 10.5Public Sector Internal Audit Standards 10.6NHS Counter Fraud Authority's counter fraud standards 10.7NHS Improvement guidance on Freedom to Speak Up Page 6 of 8 Appendix A Information and recommendations Council of Governors Board of Directors Audit and Risk Committee Finance, Investment and Cash Committee People and Organisational Development Committee Quality Committee Remuneration and Appointment Committee Page 7 of 8 Audit and Risk Committee Terms of Reference Document Monitoring Information Approval Committee: Board of Directors Date of Approval: 10 March 2026 Responsible Committee: Audit and Risk Committee Version: 8 Monitoring (Section 9) for Completion and Presentation to Approval Committee: Target audience: Key words: Main areas affected: Summary of most recent changes if applicable: Consultation: Number of pages: Type of document: Does this document replace or revise an existing document? Should this document be made available on the public website? Is this document to be published in any other format? January 2027 Board of Directors, Audit and Risk Committee, NHS Regulators, Staff and Public Audit, Risk, Committee, Board, Terms of Reference Trust-wide Appendix A – Finance, Investment and Cash Committee name change. Council of Governors, Internal Audit, External Audit, Counter Fraud 8 Committee Terms of Reference Yes Yes No Page 8 of 8
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2026-Trust-documents/Audit-and-Risk-Committee-ToR-March-2026.pdf

BRC Research-imaging-proposal-form_v2 2025 FINAL

Description
BRC Research Imaging Proposal form The BRC Research Imaging Proposal form should be completed by the chief/principal investigator of any new research study requiring access to imaging resources at University Hospital Southampton. The BRC Imaging Research Panel (BRC IRP) will use this information to determine the availability of resource and provide advice on costings for imaging research. This form should be completed before a full submission to this pilot scheme is made, to enable accurate timings/costings for the MR imaging to be determined. For the BRC MRI pump-priming research project award, this form will provide imaging specific background information, to help assess the feasibility of the project, alongside the full award application form. Please complete both Part 1 and Part 2 (detailed application). If detailed information is not known then please complete as much as possible (especially for Part 2), submit the form and we will be in contact to assist with this. Part 1 – Expression of interest Study title: Short title: Research question / summary of imaging requirements: Investigator: Email: Are you acting in your capacity as a UHS or UoS principal investigator? Select one only. UHS (Trust) UoS (University) Principal grant admin (n/a for BRC pump priming scheme) UHS (Trust) UoS (University) Other Part 2 – Detailed application Proposed start date: Proposed end date: Number of subjects: Statistical advice sought? Please circle Yes / No Type of study: Part of a multi-centre trial? Please circle Yes / No Approvals required? Please state Imaging required Imaging protocol (state if new or existing and who this has been discussed with) Frequency/timing/routine? Hardware/software/data storage/archiving and image processing and image analysis requirements? 1. 2. 3. 4. New imaging protocols (including MRI sequences) should be discussed with the MRI Research Radiographer, MRI Physics and relevant Consultant Radiologist (if required). Existing imaging protocols should be confirmed with the MRI Research Radiographer and relevant MRI Superintendent Radiographer (including protocol name and version date). Please indicate if each imaging event is routine (i.e. part of clinical care), additional as part of this proposal, and whether this will continue once the trial has ended. Hardware/software/data storage and post-processing requirements, including image archiving, should be discussed with radiology/medical physics/UoS. Please sign electronically to indicate that you have read and agree with the attached Joint UHS and UoS Policy for imaging research in Southampton and BRC award terms and conditions Name: Signature: Date: Please submit to the RIMG (on behalf of the BRC) by emailing: Angela.Darekar@uhs.nhs.uk Joint UHS and UoS policy for imaging research in Southampton – BRC/MRI specific Version 2, December 2019, Research Imaging Management Group This Joint Policy applies to any academic activity, hereby referred to as “Project”, which involves imaging or imaging results at UHS, whether it is research, case report, case series, audit, service evaluation or other description not specifically mentioned here. Planning and costing research 1. For research only: please inform RIMG (by emailing Angela.Darekar@uhs.nhs.uk) of the research at least one month prior to grant/award application form submission by completing the attached form 2. Please discuss protocols with the appropriate radiographer/radiologist/medical physicist assigned to the project by the Radiology Research Coordinator. This will ensure that accurate costings (or equivalent hours of scanning time) can be provided. 3. When costing grant applications, the Radiology Research team will advise on costing attribution across institutions. Ethical approval 1. The appropriate Health Research Authority and institutional (UHS or UoS) approvals need to be in place before the Project starts. Bookings 1. Please provide as much notice as possible for research bookings (at least 48 hours), and appreciate that they cannot always be accommodated at short notice. If particular procedures/personnel are required for bookings, these should be discussed with the Radiology Research team before RIMG approval is granted. 2. Liaise with the research radiographers for bookings, copying in RadiologyResearch@uhs.nhs.uk and provide: Name, DoB, Address, GP details, hospital ID (if available) and patient’s study ID. 3. Please use either the radiology research referral form or electronic requesting. Please clearly indicate the project title in the request and indicate that this is a research scan. Overlap between research and clinical imaging 1. If requesting clinical imaging that will later be used for research purposes, please clarify this to the reporting radiologist on the request form. Appropriate funding and ethical approvals must be in place. Publication 1. If manuscripts arise from Projects which make use of imaging data reported by UHS radiologists or involving UHS medical physicists, co-authorship or acknowledgement of these individuals should be discussed with them at the point of manuscript preparation. 2. Please include both UHS and UoS as affiliations, unless none of the authors have a honorary or substantive connection with UoS, and no use was made of any UoS facility. Please abide by the “Joint Partnership Policy and Guidance on Pre-clinical and Clinical Research Publications” v2.6, jointly approved by UHS and UoS. 3. Acknowledge resources (staff, space or equipment) of a particular imaging unit or department if these have been used. 4. Please remember to acknowledge any sponsorship you have received. 5. Please acknowledge BRC support using wording in section 4.5 below 6. For grants, please include the grant number and source. 7. Please inform RIMG of publications arising from imaging performed at UHS. Incidental findings 1. It is the recommendation of the RIMG that the Research Ethics Committee approved protocol defines precise instructions on how to consent for and manage incidental findings. These should specify a named clinician who will be responsible for managing incidental findings (reported by the radiologist(s) associated with the study) including informing the subject, arranging follow up tests and liaising with the GP as necessary. In the absence of clarity in the study protocol of any aspect relating to incidental findings, the Royal College of Radiologists’ guidance (https://www.rcr.ac.uk/publication/management-incidental-findings-detected-during-research-imaging), will need to be adhered to. Data management 1. Please ensure that data uploads/transfers and archiving processes have been discussed with the relevant people within PACS/Radiology Research/Medical Physics (as appropriate) and have been funded accordingly (to be confirmed for the BRC MRI pump-priming scheme). 2. Please ensure that all data management is in compliance with the General Data Protection Regulation or its UK equivalent. The award will only be made available if you meet the following conditions: BRC award terms and conditions 1. The award is subject to the terms and conditions of the BRC4 Research Contract signed by the Department for Health and Social Care and University Hospital Southampton NHS Foundation Trust on 8th November 2022. Specific applicable BRC terms are set out in Schedule 1 attached to this award letter. 2. The BRC funding is subject to the terms and conditions detailed in the BRC Collaboration Agreement signed by University Hospital Southampton NHS Foundation Trust and the University of Southampton, dated 15th September 2023. 3. Any additional grant funding secured by the postholder as a result of the BRC funding will be considered as grant income to the BRC. As the successful applicant awarded funding you will be required to: * Provide the BRC Manager with progress reports as requested by them, including a report at least 1 month prior to award end, plus information required to meet reporting requirements for NIHR, such as dates of submission of external applications * Contribute to the relevant School/Faculty conference and seminar programmes and BRC and NIHR-related training and development events in accordance with NIHR guidance. * Include an acknowledgement of NIHR Southampton BRC support on all publications, posters and other outputs resulting from this award. Schedule 1 – Specific Applicable NIHR Southampton Biomedical Research Centre Terms 1 Definitions: 1.1 "Award” means the funding applied for in this application. 1.2 BRC Manager means the member of staff at UHS employed to have overall management responsibility for the BRC. 1.3 “BRC Research Contract” means the Biomedical Research Centre grant contract signed by University Hospital Southampton NHS Foundation Trust and the Department for Health and Social Care and which is incorporate by reference, to the Award Letter. 1.4 “Background IP” means any Intellectual Property in existence at the commencement of the Research or created, devised or generated other than in the performance of the Research and which is actually used in the performance of the Research. 1.5 “Confidential Information” means all information of a commercially sensitive nature including (but not limited to) specifications, drawings, circuit diagrams, tapes, discs and other computable readable media, documents, techniques and know-how which are disclosed by one Party to the other for use in or in connection with the BRC or any Research. 1.6 “Foreground IP” means any Intellectual Property (and/or property right in Samples) that is created, generated or developed (whether in whole or in part) during the course of and for the purpose of any part of the Research. 1.7 “Parties” means Awardee and University Hospital Southampton NHS Foundation Trust. 1.8 “Research” means the project undertaken supported by the Award. 1.9 “Research Data” means information or data that is collected, collated or generated in the performance of the Research and includes (but is not limited to) information or data that is presented or stored in searchable form. For the avoidance of doubt, Research Data: a) does not include, without limitation, information or data that has been analysed as part of the Research; b) does include, but is not limited to, images. 1.10 “Samples” means material (including but not limited to biological material, organisms and chemical compounds), specimens or extracts collected, obtained or generated (whether in whole or in part) during the course of and for the purpose of any part of the Research. 1.11 “UHS” means University Hospital Southampton NHS Foundation Trust. 2 Intellectual Property 2.1 Awardee shall promptly report all Foreground IP to UHS. 2.2 Each Party shall own the Research Data and Foreground IP generated by it under the BRC or Project and the terms of clauses 11, 16 and 17 of BRC Research Contract shall apply to the use, management and exploitation of Research Data and Foreground IP. 2.3 Nothing contained in the Award Letter related to this funding shall affect the absolute and unfettered rights of each Party in all inventions, discoveries and intellectual property contained in its Background IP. 2.4 Subject to the BRC Research Contract, each Awardee shall undertake and continue at its expense the timely prosecution and maintenance of all Foreground IP which is solely owned by Awardee. In the event that the Awardee is unable or unwilling to comply with its obligation under this Clause 2.4, UHS and Funder shall consider how best to deal with such Foreground IP and shall have the option to require an assignment of such Foreground IP to the other Party to enable prosecution and maintenance of such Foreground IP by that other Party at its own cost. In the event that any Party wishes to exploit commercially any Foreground IP assigned pursuant to this Clause 2.4 that Party shall pay to the assigning Party a royalty and/or other appropriate form of remuneration which is fair and reasonable taking into consideration the factors set out under Clause 3.3. 2.5 In the event that any of the Parties are jointly responsible for generating Research Data and/or Foreground IP such Research Data and/or Foreground IP shall be jointly owned by the Parties. Ownership in Foreground IP shall be in accordance with the inventive contribution made by each Party to the generation of such Foreground IP and ownership in Research Data shall be in accordance with the relative contributions of each Party to the generation of the Research Data. 2.6 Joint owners of Foreground IP shall agree between them on who shall be responsible for the timely prosecution and maintenance of all such Foreground IP and the Party that is nominated to be so responsible shall be entitled to charge the other joint owners with a percentage of the costs of so doing as agreed between the joint owners. In the absence of any agreement to the contrary between joint owners the costs shall be equally shared. 3 Exploitation of Intellectual Property 3.1 Each Party grants to the other Party a non-exclusive, royalty-free licence (without the right to sublicence) to: 3.1.1 use its Research Data and Foreground IP for their own non-commercial research and development purposes but not for the purposes of commercial exploitation; and 3.1.2 in the case of UHS to use University of Southampton Research Data and Foreground IP in clinical activities within UHS; 3.1.3 subject to any existing third party obligations, use its Background IP for the purpose of undertaking the BRC and to enable the use of the Foreground IP pursuant to Clause 3.1.1 and 3.1.2 but not for the purposes of commercial exploitation. 3.2 The Parties will review and consider the optimum use of all Research Data and Foreground IP and agree which is the most suitable to effectively exploit or disseminate any Research Data and Foreground IP, subject to approval of the Funder. 3.3 In the event that any Party wishes to exploit commercially Foreground IP owned by the other Party, the owner of the Foreground IP shall grant to such Party a non-exclusive licence to use such Foreground IP for that purpose, subject to the agreement of appropriate terms in relation thereto, including a royalty and/or other appropriate form of remuneration which is fair and reasonable taking into consideration the respective financial and technical contributions of the Parties concerned to the development of the Foreground IP, the expenses incurred in securing intellectual property protection thereof and the costs of its commercial exploitation and any use of Background IP. 3.4 Should any of the Parties wish to exploit its own Foreground IP with a third party during the duration of the BRC, that Party must notify the other Party before approaching said third party, always provided that the disclosure of information required for such exploitation is subject to the obligations of confidentiality at least equivalent to those under Clause 11. Further any necessary notification to NIHR shall be made and their respective approval should be obtained or commercialisation agreement in place, if required, prior to exploitation. 3.5 In recognition of the Parties joint involvement with the BRC and the contribution to development of the Foreground IP a Party exploiting its own Foreground IP will provide a fair revenue share to the other Party. In the event any revenues are due to the Funder revenues shall first be distributed to the Funder prior to sharing between the Parties. 3.6 Subject to Clause 3.4 each Party agrees (where it is free and reasonably able to do so) to license on fair and reasonable terms its Foreground IP and Background IP that may be required to enable any other Party to exploit its own Foreground IP or Background IP, always subject to the obligations of confidentiality under Clause 5. 3.7 With regard to joint inventions, the Parties owning such inventions agree to co-operate fully in the protection of such joint inventions and each Party shall be entitled to make use of such joint inventions subject only to negotiating a licence in good faith from the other Party for its interest in such joint inventions on similar terms to those set out in clause 3.3. 3.8 The University shall grant to the Funder a non-exclusive, irrevocable, royalty-free, worldwide licence together with the right to grant sub-licences to health service bodies or others directly engaged in providing health care, permitting the Funder to use and publish 3.9 any information relating to the Research which is not Confidential Information of the University 3.9.1 any Foreground IP; 3.9.2 Research Data; 3.9.3 Reports; 3.9.4 arising know how; and, 3.9.5 conclusions arising from the Research 3.10 and in each case, the University acknowledges the Funder intends to exercise this right only where the Funder’s reasonable opinion the University is not appropriately managing, disseminating or using such items and in each case Funder is permitted to use or make available such items as it sees fit in support of: (i) the development, promotion or provision of health care that is not a commercial use; and/or (ii) for any other purpose that is not a commercial use. 4 Publication 4.1 Subject to the provisions of Clauses 2, 3 and 5 neither Party shall disclose or publish information or Foreground IP for the duration of the BRC and for 3 (three) years thereafter without the consent of the other Party , such consent, not to be unreasonably withheld or delayed. Further the Parties must seek to obtain all necessary consents from NIHR and any Collaborating Parties prior to publication. The obligation to seek consent of NIHR or continues after the end of the Research. 4.2 Subject to 4.1, the Parties shall be permitted to publish the Research Data of the BRC which they have undertaken in accordance with normal academic practice, subject always to the provisions of Clauses 8 and 5, and providing such disclosure does not jeopardise any application for Foreground IP protection by any Party. Request for such consent must be submitted together with the material proposed for publication to the BRC Manager. If any Party can reasonably demonstrate that such a disclosure contains material that would prejudice the value of any Background IP and/or Foreground IP, that Party shall inform the BRC Manager in writing within 28 days of that Party receiving a copy of the proposed publication and in that event the disclosure shall be amended so as to meet the objections of that Party or delayed to address their concerns. 4.3 Subject to the provisions of Clause 3 where in the opinion of UHS a proposed publication contains patentable or commercially sensitive subject matter which needs protection then the Party proposing to publish may be requested to refrain from doing so for a maximum of six 6 months in order to allow for application for patent protection in the name and at the cost of the relevant owner of the Foreground IP. The provisions of Clause 2 and 3 shall apply in respect of any licence to such Foreground IP. 4.4 Nothing contained in the Award Letter related to this funding shall prevent the submission of a thesis to examiners in accordance with the normal regulations of the Parties subject where appropriate to such examiners being bound by conditions of confidentiality in no less terms than those outlined in Clause 5 nor to the placing of such thesis in the library of the appropriate Research Party provided that access to such thesis shall only be available on conditions of confidentiality no less onerous than those contained in Clause 5 hereof. 4.5 The University shall ensure that all project investigators acknowledge in all theses, papers and other publications (including from non-BRC projects) that they receive support from the NIHR Southampton BRC, in accordance with BRC Research Contract. The form of words is: “[investigator initials] is supported by the National Institute for Health and Care Research through the NIHR Southampton Biomedical Research Centre”. 4.6 The Parties acknowledge that NIHR is entitled to publish the whole or any part of the Report. If the Parties wishes NIHR to delay such publication, it must submit a request in writing to the NIHR giving reasons for the requested delay which shall be considered in accordance with the NIHR’s Information for Authors’ Dual Publication Guidance and Embargo Policy as defined in the NIHR Contract and amended from time-to-time. 4.7 Neither Party shall use the other's name, crest, logo or registered image for any purpose without the express permission of the other Party. The Parties will agree treatment for referencing each others involvement in the BRC and joint branding for their activities subject to compliance with Clause 4.8 and the BRC Research Contract. 4.8 Neither Party shall issue any press release, public statement, or other media announcement related to the BRC or any Research Data or Foreground IP without the prior consent of the other Party and Funder, as applicable. 4.9 The Parties (in the case of the University via UHS must notify the Funder of any intention to issue a press release at least three (3) business days prior to any press release issued by it or on its behalf, directly related to the Research or Foreground IP, arising now how or Research Data or of matters arising from such Research. Awardee shall send one draft copy of the proposed press release to UHS at least five (5) business days before the date intended for release. For the avoidance of doubt this obligation shall continue in full force and effect following expiry of the Award letter 4.10 The Parties shall comply with guidance and advice from Funder on branding and publicity which may be issued from time to time including, but not limited to Funder’s guidance on the format for websites, press releases and use of social media, permitted use of the NIHR, BRC, NHS and Department of Health and Social Care brands, names and logos and ensuring all branding references to the BRC are prefixed with the term “NIHR”. 5 Confidentiality 5.1 The Parties hereto agree to use all reasonable endeavours to ensure that any Confidential Information disclosed or submitted in writing or any other tangible form to one Party (“Receiving Party”) by the other (“Disclosing Party”) shall be treated with the same care and discretion to avoid disclosure as the Receiving Party uses with its own similar information which it does not wish to disclose. Any information disclosed orally that is identified by the Disclosing Party as Confidential Information shall be treated the same as if it had been reduced to writing at the time of disclosure to the Receiving Party. 5.2 The Receiving Party shall not, during a period of seven (7) years after the termination of this Award Letter, use any such Confidential Information for any purpose other than the carrying out of its obligations under this Award funding or other than in accordance with the terms of this Award funding. 5.3 The undertaking in Clause 5.1 above shall not apply to Confidential Information: 5.3.1 which, at the time of disclosure, has already been published or is otherwise in the public domain other than through breach of the terms of this Award funding; 5.3.2 which, after disclosure to the Parties, is subsequently published or comes into the public domain by means other than an action or omission on the part of any of the Parties; 5.3.3 which a Party can demonstrate was known to him or subsequently independently developed by them; 5.3.4 lawfully acquired from third parties who had a right to disclose it with no obligations of confidentiality to any of the Parties; or 5.3.5 is required to be disclosed by applicable law or court order or by any Party's regulatory body, which is empowered by Statute or Statutory Instrument, but only to the extent of such disclosure and the Receiving Party shall notify the Disclosing Party promptly of any such request. 5.4 Staff and students and any agents, consultants or sub-contractors engaged to work on the BRC will be subject to the principles of confidentiality outlined in this Clause 5. 6 Term and Termination 6.1 The terms of this award shall come into force on the date when the Acceptance Statement is signed by the Awardee and remain in full force and effect until 31st March 2028 unless terminated earlier in accordance with the provisions of this Clause 6. 6.2 In the event that any Party shall commit any breach of or default in any terms or conditions of this Award funding, the other Party may serve written notice of such breach or default on the defaulting Party and in the event that such Party fails to remedy such default or breach within sixty (60) days after receipt of such written notice the other Party may, at their option and in addition to any other remedies which they may have at law or equity, terminate this Award funding by sending notice of termination in writing to the other Party. 6.3 If any Party (a) materially breaches any provisions of this Award funding ; or (b) passes a resolution for its winding-up; or if (c) a court of competent jurisdiction makes an order for that Party’s winding-up or dissolution; or makes an administration order in relation to that Party; or if any Party (e) appoints a receiver over, or an encumbrancer takes possession of or sells an asset of, that Party; or (f) makes an arrangement or composition with its creditors generally; or (g) makes an application to a court of competent jurisdiction for protection from its creditors generally; the other Party may terminate their involvement in the BRC. 6.4 In the event the BRC Research Contract terminates UHS may terminate this Award funding with immediate effect. 7 General 7.1 Each Party shall indemnify each of the other Parties, within the limits set out in this Clause 6, in respect of liability resulting from acts or omissions of itself, its employees or its students provided always that such indemnity shall not extend to claims for indirect or consequential loss or damages such as, but not limited to, loss of profit, revenue, contracts or the like. 7.2 Any amendments to this Award funding shall be valid only if made in writing and signed by authorised signatories of the Parties. 7.3 If any part or any provision of this Award funding shall to any extent prove invalid or unenforceable in law the remainder of such provision and all other provisions of this Award funding shall remain valid and enforceable to the fullest extent permissible by law, and such provision shall be deemed to be omitted from this Award funding to the extent of such invalidity or unenforceability. The remainder of this Award funding shall continue in full force and effect and the Parties shall negotiate in good faith to replace the invalid or unenforceable provision with a valid, legal and enforceable provision which has an effect as close as possible to the provision or terms being replaced. 7.4 No failure to exercise or delay in the exercise of any right or remedy which any Party may have under this Award funding or in connection with this Award funding shall operate as a waiver thereof, and nor shall any single or partial exercise of any such right or remedy prevent any further or other exercise thereof or of any other such right or remedy. 7.5 This Award funding including its Schedule supersedes all other agreements and understandings, whether written or oral, between the Parties about the BRC constitutes the entire agreement between the Parties regarding the BRC. 7.6 Except as otherwise expressly provided for herein, the Parties confirm that nothing in this Award funding shall confer or purport to confer on any third party any benefit or any right to enforce any term of this Award funding for the purposes of Contracts (Rights of Third Parties) Act 1999. 7.7 This Award funding shall be governed by and construed in accordance with English Law and each Party agrees to submit to the exclusive jurisdiction of the English Courts as regards any claim or matter arising under this Award funding. Page 4 of 6
Url
/Media/Southampton-Clinical-Research/Downloads/BRC-Research-imaging-proposal-form-v2-2025-FINAL.docx

Finance, Investment and Cash Committee ToR October 2025

Description
Finance, Investment and Cash Committee Terms of Reference Date Issued: Review Date: Document Type: 7 October 2025 October 2026 Committee Terms of Reference Version: 11 Contents Paragraph 1 2 3 4 5 6 7 8 9 10 Role and Purpose Constitution Membership Attendance and Quorum Frequency of Meetings Conduct and Administration of Meetings Duties and Responsibilities Accountability and Reporting Review of Terms of Reference and Performance and Effectiveness References Appendices Appendix A Appendix B Committee and Reporting Structure Operational Cash Group Terms of Reference Page 2 2 2 3 3 3 4 6 6 6 Page 7 8 Document Status This is a controlled document. Whilst this document may be printed, the electronic version posted on the intranet is the controlled copy. Any printed copies of this document are not controlled. As a controlled document, this document should not be saved onto local or network drives but should always be accessed from the intranet. Page 1 of 10 1. Role and Purpose 1.1 The Finance, Investment and Cash Committee (the Committee) is responsible for overseeing, monitoring and reviewing the stewardship of the Trust’s finances, investments and sustainability of University Hospital Southampton NHS Foundation Trust (UHS or the Trust), including planning, financial performance, cash management, capital expenditure and the delivery of the informatics and estates, facilities and capital development annual plans. 1.2 The Committee provides the board of directors of the Trust (the Board) with a means of assurance regarding the Trust’s financial position and capital and revenue investments to enable world-class people to deliver world-class care. 1.3 The duties and responsibilities of the Committee are more fully described in paragraph 7 below. 2. Constitution 2.1 The Committee has been established by the Board. The Committee has no executive powers other than those set out in these terms of reference. It is supported in its work by other committees established by the Board and other committees and groups as shown in Appendix A. 2.2 The Committee is authorised by the Board to investigate any activity within its terms of reference. It is authorised to seek any information it requires from any member of staff and all members of staff are directed to cooperate with any request made by the Committee. 2.3 In carrying out its role the Committee is authorised to seek reports and assurance from executive directors and managers and will maintain effective relationships with the chairs of other Board committees to understand their processes of assurance and links with the work of the Committee. 2.4 The Committee is authorised to obtain external legal or other independent professional advice if it considers this necessary, taking into consideration any issues of confidentiality and the Trust’s standing financial instructions. 3. Membership 3.1 The members of the Committee will be appointed by the Board and will be: 3.1.1 three non-executive directors of the Trust, at least two of whom should be independent, including the chair of the Audit and Risk Committee; 3.1.2 the Chief Executive Officer; 3.1.3 the Chief Financial Officer; and 3.1.4 the Chief Operating Officer. 3.2 The Board will appoint the chair of the Committee from among its non-executive director members (the Committee Chair). The Committee Chair will not be the chair of the Audit and Risk Committee. In the absence of the Committee Chair and/or an appointed deputy, the remaining members present will elect one of themselves to chair the meeting. 3.3 To ensure that non-executive directors hold the majority of votes on the Committee, only the Chief Financial Officer and Chief Operating Officer shall be invited to vote on any matter. The Committee Chair will have a second and casting vote in the event of a tie. Page 2 of 10 3.4 Subject to paragraph 3.3 above, only members of the Committee have the right to attend and vote at Committee meetings. However, the following will be invited to attend meetings of the Committee on a regular basis: 3.4.1 Director of Operational Finance/Deputy Director of Finance; 3.4.2 Director of Planning, Performance and Productivity; and 3.4.3 Associate Director Always Improving. 3.5 Other individuals may be invited to attend for all or part of any meeting, as and when appropriate and necessary, particularly when the Committee is considering areas of risk or operation that are the responsibility of a particular executive director or manager. 3.6 Governors may be invited to attend meetings of the Committee. 4. Attendance and Quorum 4.1 Members should aim to attend every meeting and should attend a minimum of 75% of meetings held in each financial year. Where a member is unable to attend a meeting they should notify the Committee Chair or Company Secretary in advance. 4.2 The quorum for a meeting will be three members, including two non-executive directors (one of whom must be either the Committee Chair or the chair of the Audit and Risk Committee) and either the Chief Financial Officer or Chief Operating Officer. A duly convened meeting of the Committee at which a quorum is present will be competent to exercise all or any of the authorities, powers and discretions vested in or exercisable by the Committee. 4.3 When an executive director or manager is unable to attend a meeting they should appoint a deputy to attend on their behalf. 5. Frequency of Meetings 5.1 The Committee will meet at least ten times each year (usually once each calendar month) and otherwise as required. 6. Conduct and Administration of Meetings 6.1 Meetings of the Committee will be convened by the secretary of the Committee at the request of the Committee Chair or any of its members. 6.2 The agenda of items to be discussed at the meeting will be agreed by the Committee Chair with support from the Chief Financial Officer. The agenda and supporting papers will be distributed to each member of the Committee and the regular attendees no later than four working days before the date of the meeting. Distribution of any papers after this deadline will require the agreement of the Committee Chair. 6.3 The secretary of the Committee will minute the proceedings of all meetings of the Committee, including recording the names of those present and in attendance and any declarations of interest. 6.4 Draft minutes of Committee meetings and a separate record of the actions to be taken forward will be circulated promptly to all members of the Committee. Once approved by the Committee, minutes will be circulated to all other members of the Board unless it would be inappropriate to do so in the opinion of the Committee Chair. Page 3 of 10 7. Duties and Responsibilities The Committee will carry out the duties below for the Trust. 7.1 Financial planning and performance 7.1.1 The Committee will review and monitor the following, ensuring these support the achievement of the Trust’s objectives, and consider the adequacy and effectiveness of any corrective action proposed: 7.1.1.1 the Trust’s long-term financial model; 7.1.1.2 the Trust’s long-term and annual financial plans encompassing income, expenditure and capital; 7.1.1.3 the capital plan including any changes in the Trust’s performance that may impact on the delivery of the long-term capital plan; 7.1.1.4 financial performance and forecasts and projections including achievement of the control total and other targets; 7.1.1.5 performance against revenue budgets at both Trust and divisional level; 7.1.1.6 capacity, activity and productivity including any significant variation and the impact on income; 7.1.1.7 cash, liquidity and working capital; 7.1.1.8 the use of any working capital facilities; and 7.1.1.9 performance of the Trust’s subsidiaries and any joint ventures against agreed performance indicators. 7.2 Cash Management 7.2.1 The Committee shall review and monitor the Trust’s overall cash position, including: 7.2.1.1 review of cash forecasts, the reasons for the Trust’s cash position, and performance against cash key performance indicators; 7.2.1.2 reviewing and monitoring of the management of financial risk and the availability of cash to meet operational requirements; 7.2.1.3 ensuring that the Trust settles with its creditors in accordance with the Government’s Better Payment Practice Code; 7.2.1.4 reviewing the level of funds owed to the Trust is minimised through effective credit control; 7.2.1.5 oversight of the cash impact of capital investments; 7.2.1.6 reviewing a monthly cash report from the Operational Cash Group. The terms of reference for the Operational Cash Group are set out in Appendix B; 7.2.1.7 reviewing the management of any surplus cash in line with the Trust’s treasury management policy. 7.2.2 The Committee shall make recommendations to the Board in respect of applications for revenue public dividend capital from NHS England. 7.3 Always Improving Value for Money 7.3.1 The Committee will ensure that there is an Always Improving: Value for Money (AIVFM) programme in place each financial year that aligns with the Trust’s annual plan. Page 4 of 10 7.3.2 The Committee will seek assurance that a recovery plan is in place and being implemented where any AIVFM schemes are at risk of delivery. 7.4 Investment 7.4.1 The Committee will review business cases of £2.5 million or more in value, ensuring that outcomes and benefits are clearly defined and measurable and support achievement of the Trust’s objectives and making recommendations to the Board for approval. 7.4.2 The Committee will review capital business cases over £5 million in value, ensuring that outcomes and benefits are clearly defined and measurable and support achievement of the Trust’s objectives and making recommendations to the Board for approval. 7.4.3 The Committee will review all business cases identified by the Trust Executive Committee as of significant strategic importance regardless of value, ensuring that outcomes and benefits are clearly defined and measurable and support achievement of the Trust’s objectives and making recommendations to the Board for approval. 7.4.4 The Committee will assess benefits realisation through post-implementation reviews, ensuring any learning is shared. 7.5 Informatics annual plan 7.5.1 The Committee will monitor and oversee the delivery of the Trust’s annual plan for IT including funding and ongoing alignment with the Trust’s objectives. 7.6 Estates, facilities and capital development annual plan 7.6.1 The Committee will monitor and oversee the delivery of the Trust’s estates, facilities and capital development annual plan including funding and ongoing alignment with the Trust’s objectives. 7.7 Risk 7.7.1 The Committee will monitor risks identified in the Trust’s Board Assurance Framework that have been allocated for oversight by the Committee. 7.7.2 The Committee will establish and maintain an overview of the Trust’s financial risks and risks to delivery of the Trust’s informatics or estates, facilities and capital development plans and ensure the effectiveness and implementation of controls for financial risks and actions to mitigate risks to the delivery of the Trust’s informatics or estates, facilities and capital development plans. 7.7.3 The Committee will refer any potential risks to patient safety or quality identified by the Committee to the Quality Committee. 7.7.4 The Committee will commission and oversee assurance deep dives into specific identified risks at the request of either the Committee Chair or the chair of the Board. 7.8 Reporting 7.8.1 The Committee will review any key financial submissions to national bodies before these are presented to the Board for approval. 7.8.2 The Committee will review the National Cost Collection Index for the purposes of benchmarking the Trust’s performance. Page 5 of 10 8. Accountability and Reporting 8.1 The Committee Chair will report to the Board following each meeting, drawing the Board’s attention to any matters of significance or where actions or improvements are needed. 8.2 The Committee will report to the Audit and Risk Committee at least annually on its work in support of the annual governance statement, specifically commenting on the financial statements and the appropriateness of the self-assessment of the effectiveness of the system of internal control and the disclosure of any significant internal control issues in the annual governance statement. 8.3 Appendix A sets out the sub-committees that report to and support the Committee in fulfilling its duties and responsibilities. 9. Review of Terms of Reference and Performance and Effectiveness 9.1 At least once a year the Committee will review its collective performance and its terms of reference. Any proposed changes to the terms of reference will be recommended to the Board for approval. 10. References 10.1National Health Service Act 2006 10.2NHS System Oversight Framework 10.3NHS Improvement and Care Quality Commission Use of Resources: assessment framework 10.4Standing Financial Instructions Page 6 of 10 Appendix A Board of Directors Audit and Risk Committee Finance, Investment and Cash Committee People and Organisational Development Committee EFCD Compliance & Governance Group Quality Committee Remuneration and Appointment Committee Operational Cash Group Transformation Oversight Group Trust Investment Group Financial Improvement Group Page 7 of 10 Appendix B Operational Cash Group Terms of Reference 1. Role and Purpose 1.1 The Operational Cash Group (the Group) is responsible for overseeing, monitoring and reviewing cash related matters for University Hospital Southampton NHS Foundation Trust (UHS or the Trust) as set out in more detail in paragraph 7. 2. Constitution 2.1 The Group has been established by the Finance, Investment and Cash Committee (the Committee). The Group has no executive powers other than those set out in these terms of reference. 2.2 The Group is authorised by the Committee to investigate any activity within its terms of reference. It is authorised to seek any information it requires from any member of staff and all members of staff are directed to cooperate with any request made by the Group. 3. Membership 3.1 The members of the Group will be appointed by the Committee and will be: 3.1.1 the Director of Operational Finance; 3.1.2 the Associate Director of Operational Finance; 3.1.3 the Financial Services Manager; and 3.1.4 members of the finance team responsible for Accounts Receivable, Accounts Payable, Capital and Management Accounts (as required). 3.2 The Group shall be chaired by the Director of Operational Finance, or in his absence, by the Associate Director of Finance (the Chair). 3.3 Other individuals may be invited to attend for all or part of any meeting, as and when appropriate and necessary. 4. Attendance and Quorum 4.1 The quorum for a meeting will be two members, including one of either the Director of Operational Finance or the Associate Director of Operational Finance. A duly convened meeting of the Committee at which a quorum is present will be competent to exercise all or any of the authorities, powers and discretions vested in or exercisable by the Group. 4.2 When a member is unable to attend a meeting, they should appoint a deputy to attend on their behalf. 5. Frequency of Meetings 5.1 The Group will meet weekly and otherwise as required. 6. Conduct and Administration of Meetings 6.1 Meetings of the Group will be convened at the request of the Chair or any of its members. 6.2 The agenda of items to be discussed at the meeting will be agreed by the Chair. 6.3 The Chair shall ensure that there is a record of the proceedings of all meetings of the Group, including recording the names of those present and in attendance and any declarations of interest. Page 8 of 10 7. Duties and Responsibilities 7.1 The Committee will carry out the duties below 7.1.1 reviewing the Trust’s actual cash position against previous forecasts and the assumptions used; 7.1.2 reviewing the trend and change over time of cash balances; 7.1.3 identifying when cash pressures will arise and suggesting mitigating actions; 7.1.4 escalating actions to the Chief Financial Officer, where appropriate; 7.1.5 reviewing the cash impact and timing of investments; 7.1.6 reviewing the Trust’s accounts receivable position, targeting timely payments to the Trust; 7.1.7 reviewing the Trust’s accounts payable position and compliance with the Government’s Better Payments Practice Code; 7.1.8 producing a monthly report to the Chief Financial Officer and Finance, Investment and Cash Committee; 7.1.9 reporting on performance against cash key performance indicators; 7.1.10 producing cash management plans for approval by the Chief Financial Officer. 8. Accountability and Reporting 8.1 The Group Chair will report to the Chief Financial Officer following each meeting, drawing his attention to any matters of significance or where actions or improvements are needed. 8.2 The Group Chair will report to the Finance, Investment and Cash Committee in accordance with the Committee’s schedule of meetings. 9. Review of Terms of Reference and Performance and Effectiveness 9.1 At least once a year the Group will review its collective performance and its terms of reference. Any proposed changes to the terms of reference will be recommended to the Finance, Investment and Cash Committee for approval. Page 9 of 10 Finance, Investment and Cash Committee Terms of Reference Version: 11 Document Monitoring Information Approval Committee: Board of Directors Date of Approval: 7 October 2025 Responsible Committee: Finance, Investment and Cash Committee Monitoring (Section 9) for Completion and Presentation to Approval Committee: Target audience: Key words: Main areas affected: Summary of most recent changes if applicable: Consultation: Number of pages: Type of document: Does this document replace or revise an existing document? Should this document be made available on the public website? Is this document to be published in any other format? October 2026 Board of Directors, Finance, Investment and Cash Committee, Staff Finance, Investment, Cash, Committee, Board, Terms of Reference Trust-wide Amendments to remit of Committee to include enhanced cash management role and renaming of Committee. Amendments to Appendix A. Addition of Operational Cash Group terms of reference in Appendix B. Chief Financial Officer 10 Committee Terms of Reference Yes Yes No Page 10 of 10
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2025-Trust-documents/Finance-Investment-and-Cash-Committee-ToR-October-2025.pdf

RViR Mentoring - Researcher Advert

Description
Raising Voices in Research: Mentoring Call for mental health researchers in Wessex Raising Voices in Research has been funded by NIHR Applied Research Collaborative Wessex (NHIR ARC Wessex) to deliver a new project ‘Raising Voices in Research Mentoring’ and we would love to invite you to apply. What is Raising Voices in Research Mentoring? Raising Voices in Research (RViR) is a project delivered by Action Hampshire, Hampshire and Isle of Wight ICB, University Hospital Southampton NHS Foundation Trust, and Engaging Communities Research Centre at University of Winchester. RViR aims to increase under-served communities participation in health and social care research. We believe this is important because if more under-served communities take part in health research, the outcomes are more likely to reflect their needs. You can read more about RViR by visiting rvir.co.uk. The focus of RViR Mentoring is to: • increase voluntary, community, and social enterprise organisations’ and their communities’ understanding of health research (including mental health research) • understand what mental health related research communities want to see • develop community-led mental health research priorities. What will it involve? Successful researchers will undertake RViR ‘Developing community-led research’ training. After which you will be matched with a voluntary, community, or social enterprise (VCSE) organisation who works with at least one of the following communities: • Children and young people who are neurodiverse and/or have a mental health condition • Older adults in coastal communities • Men with a mental health condition • Military personnel/veterans You will work together through a series of monthly meetings to exchange knowledge and ideas to either: • develop a new research proposal based on the community’s mental health research priorities and your area of expertise OR • adapt on existing research proposal/opportunity based on the community’s needs (that they will have identified through previous project work) Researchers and VCSEs will be expected to work together from September 2025 – February 2026. Who can apply? Any researcher within Wessex who has expertise or interest in mental health research. You must have capacity to meet with your matched VCSE organisation at least once per month from September 2025 – February 2026. Why should I take part? Community-led research is becoming increasingly important, with patient and participant involvement and engagement a compulsory part of all NIHR research projects. Participating in RViR Mentoring will support you to complete this element of your work, learn more about effective community engagement, and allow you to develop strong working relationships with key communities. What support will I get? • Invitation to participate in the RViR ‘Developing community-led research’ training module • A grant of £1000 will be made available to support your participation in the project. This can be used for travel, equipment, materials or other support needs. • 1:1 support from a member of the RViR team as part of the matching process with a VCSE How do I apply? To apply, please complete the short application form: https://forms.office.com/e/60ewCwbEML The deadline to apply is Monday 30th June 2025. Decisions will be communicated to applicants by the end of July 2025. Any questions? If you’d like to discuss this opportunity further or have any questions, please contact Jess Johnson by emailing jessica.johnson@actionhampshire.org
Url
/Media/Southampton-Clinical-Research/Downloads/RViR-Mentoring-Researcher-Advert.pdf
241 to 250 of 433
Previous … 23 24 25 26 27 … Next